Cassava Sciences | PTIE - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Abbott USD 8.52B 1.01B 2025-12
Amgen USD 9.13B 316M 2025-12
Biogen USD 3.01B 854.3M 2025-12
Cara Therapeutics USD 21.42M 770K 2025-09
Cassava Sciences USD 106.08M 6.3M 2025-09
Eisai JPY 301.65B 16.27B 2025-09
Eli Lilly USD 7.27B 2.52B 2025-12
Geron USD 79.44M 553K 2025-12
J&J USD 19.71B 1.48B 2025-12
Merck USD 18.17B 10.16B 2025-09
Novartis USD 9.56B 2.9B 2025-09
Novavax USD 240.63M 27.39M 2025-12
Pfizer USD 1.34B 295M 2025-09
Roche Holding CHF 7.55B 579M 2025-06